Loading...
Diffuse large B-cell lymphoma (DLBCL) can be divided into broad subtypes with distinct molecular and phenotypic signatures: Patients who have germinal center B-cell–like (GCB) DLBCL generally have more favorable treatment outcomes and longer survival than those who have activated B-cell (ABC) or other non-GCB signatures. A hallmark feature of ABC and non-GCB DLBCL that is suspected to contribute to poorer outcomes is the constitutive activation of the nuclear factor kappa beta (NF-κB) signaling pathway. To determine molecular mechanisms underlying NF-κB pathway activation, investigators analyzed DNA from patient samples and DLBCL cell lines for mutations in positive and negative NF-κB regulatory elements.
Mutations were identified in several…